Japanese drugmaker Takeda (TYO: 4502) reported a rise in revenue at the end of Japan’s 2021/22 financial year, but saw a significant drop in its profits.
Takeda’s reported revenue rose 11.6% to 3,569 billion yen ($27.51 billion), though its 12-month operating profit slid 9.5% to 460.8 billion yen. The absence of one-time gains seen in fiscal 2021 was to blame for the reduction, the company said.
The profit figure compares with Takeda’s earlier estimate of 515 billion yen and a consensus forecast of 509 billion yen from a Refinitiv poll of 15 analysts .Looking ahead, Takeda estimated that the current fiscal year's operating profit would hit 520 billion yen, an increase of nearly 13%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze